Magnesium lauryl sulfate supplied as a veterinary-grade anionic surfactant API is incorporated into direct-compression and wet-granulation tablet cores for companion animal anthelmintics and oral antimicrobials at 0.25–1.5 wt% of the total core mass. The divalent magnesium counterion lowers the equilibrium moisture uptake of the granulation compared with sodium lauryl sulfate under storage at 25 ± 2 °C and 60 ± 5% RH, as determined by dynamic vapour sorption; this is relevant because water activity above 0.60 activates microbial growth pathways in non-sterile veterinary tablets governed by USP <61> and USP <62>. In a high-shear granulator operating with an impeller tip speed of 4–6 m/s, magnesium lauryl sulfate reduces the surface tension of a 2.5 wt% aqueous povidone binder solution to approximately 28–32 mN/m, shifting the granulation endpoint from time-based water addition to torque-based liquid addition. Because the wet-mass torque rise is less steep than in surfactant-free batches, the operator must recalibrate the endpoint from 18–22% added binder to a torque-equivalent endpoint to avoid dense, over-granulated agglomerates that fail disintegration under USP <701>. The surfactant is pre-sieved through a 500 µm stainless-steel mesh before dry blending with lactose monohydrate or dicalcium phosphate dihydrate. Blend uniformity is assessed by stratified Near-Infrared spectroscopy with a method validated under ICH Q2(R1); acceptance is RSD ≤ 5.0% for active substance and magnesium lauryl sulfate, while finished tablets are tested for content uniformity in accordance with USP <905> with an acceptance value of ≤ 15.0. Compression on a rotary tablet press fitted with 10.0 mm round concave tooling is maintained at a main compression force of 8–15 kN, producing immediate-release tablet cores with hardness of 50–90 N measured on a Schleuniger tablet hardness tester and friability below 1.0% after 100 rotations per USP <1216>. Dissolution of the finished tablet is verified with USP <711> Apparatus 2 at 50 rpm in 900 mL degassed 0.1 M hydrochloric acid at 37.0 ± 0.5 °C; a typical acceptance limit for immediate-release veterinary boluses is ≥ 80% release in 30 min. The completed tablets are packed in aluminium/aluminium blister cavities with a desiccant when the internal water activity exceeds 0.60; this packaging decision is supported by a stability study conducted at 40 ± 2 °C and 75 ± 5% RH for 6 months following ICH Q1A(R2).

Can Magnesium Lauryl Sulfate Clear the Sterility Barrier Without Raising Particulate Load in Injectable Suspensions?

In injectable veterinary suspensions, magnesium lauryl sulfate functions as a crystal-surface wetting agent for poorly water-soluble actives intended for intramammary infusion, subcutaneous depot injection, or non-intravenous antiparasitic delivery. The upper concentration limit in this application is constrained by erythrocyte membrane disruption potential of anionic surfactants rather than by solubility; in vitro haemolysis testing performed under ISO 10993-4:2017 is used to reject any formulation that produces measurable haemolysis above the blank control at the intended injection-site concentration. Working concentrations of magnesium lauryl sulfate in sterile suspensions are typically maintained at 0.01–0.05 wt%; above this range, plasma protein binding interference and local tissue irritation observed in rabbit paravascular irritation models limit further use. The suspension is prepared by dispersing the active substance in a continuous phase containing magnesium lauryl sulfate, followed by high-shear mixing at 8,000–12,000 rpm for 5–10 min and subsequent high-pressure homogenisation at 800–1,200 bar for 3–5 passes. The resulting particle size, expressed as D₉₀, is controlled below 10 µm for intramuscular suspensions and below 20 µm for intramammary preparations; particle size is verified by laser diffraction following USP <429>. Terminal sterilisation at 121 °C for 15 min is acceptable only if the active substance is thermally stable; otherwise, aseptic filtration through a 0.22 µm sterilising-grade filter is used, provided the suspension particle size remains filterable. Sterility is confirmed by USP <71>, subvisible particulate matter by USP <788>, visible particulates by USP <790>, and bacterial endotoxin by USP <85> with a typical limit of < 2.5 EU/mL for intramammary products. Because magnesium lauryl sulfate is anionic, it is incompatible with cationic preservatives such as benzalkonium chloride and with high-hardness water containing calcium above 120 ppm as CaCO₃; these incompatibilities can produce visible precipitation and should be avoided in the formulation vehicle. For intravenous, intra-articular, or epidural administration, published data for this specific configuration is limited, and extension beyond the non-intravenous routes is not supported without acute local tolerance testing and complete haemocompatibility evaluation.

When Tricompartment Capsule Fillers Encounter an Anionic Surfactant at the Dosator Interface

Automatic hard gelatin capsule filling with magnesium lauryl sulfate-containing powder blends requires deliberate moisture and antistat control because the surfactant changes the cohesive/adhesive force balance at the dosator pin. The surfactant is added at 0.3–1.0 wt% of the fill mass and preblended with colloidal silicon dioxide at 0.2–0.5 wt% to minimise segregation during tumble blending in a V-blender rotated at 15–25 rpm for 10–15 min. The resulting blend should have an angle of repose below 35°, a compressibility index below 20%, and a Hausner ratio below 1.20, measured by USP <616> and USP <1174> for powder flow. On a dosator-type capsule filler operating at 60,000 capsules/hour, plug ejection weight fluctuations are held within ±3% of target by maintaining powder bed depth above 40 mm and dosator pin compression at 5–10 mm penetration; loss-on-drying of the blend before filling is controlled at 1.0–2.5% by USP <731>. The filling suite is maintained at 25 ± 2 °C and 35–40% RH because below 30% RH static charges on gelatine shells increase rejection rates due to powder cling on the inner cap surface, while above 50% RH gelatine shell softening increases the incidence of telescoping and splitting. Content uniformity is evaluated by USP <905> with an acceptance value of ≤ 15.0, and dissolution is monitored by USP <711> Apparatus 1 at 100 rpm in 900 mL purified water at 37.0 ± 0.5 °C. The surfactant reduces dissolution lag time by lowering the contact angle between the capsule contents and the dissolution medium; however, this benefit is lost if the formulation is stored above 40 °C for more than 3 months, where magnesium lauryl sulfate can promote cross-linking in gelatine shell films through hygroscopic stress. Finished capsules are size 3 to 0 for canine and porcine oral administration, with shell moisture held below 13% w/w and total aerobic microbial count below 10³ CFU/g according to USP <1111> category 3 readiness.

When water-soluble veterinary oral powders for poultry and swine are reconstituted in drinking water, the compound is used as a deagglomeration aid for hydrophobic, micronised actives that otherwise clump upon wetting. The inclusion rate is typically 0.05–0.2 wt% of the total powder mass, while the active substance is milled to a particle size where at least 90% passes through a 100 µm sieve as determined by USP <786>. The manufacturing process involves a low-shear ribbon blender operated at 10–15 rpm for 10–20 min after the active substance and water-soluble carrier are pre-blended; magnesium lauryl sulfate is then added as a trituration pre-mix at 1:99 by weight to avoid localised surfactant overload. Blend uniformity is assessed by withdrawing 10 stratified samples from the ribbon blender after 10, 15, and 20 min mixing intervals; the active substance content in each sample, determined by validated HPLC under ICH Q2(R1), must show RSD ≤ 5.0% and no single result outside 90.0–110.0% of label claim. Moisture content is controlled below 2.0% by USP <731> because free water above this threshold converts the surfactant into a sticky hydrate that impairs sieving and promotes microbial proliferation. The finished powder is filled into foil-lined sachets under nitrogen overlay when the active substance is oxygen-sensitive; sachet seal integrity is tested according to ASTM F88/F88M-21 with a minimum seal strength of 1.5 N/15 mm. The terminal product is reconstituted in drinking water at 0.5–2.0 g/L and should be used within 24 hours after mixing; this limit is derived from in-use stability testing in which magnesium lauryl sulfate reduces surface tension but does not provide antimicrobial preservation.

Granule porosity and wetting rate after top-spray fluidised-bed agglomeration

Fluidised-bed granulation for veterinary oral granules containing magnesium lauryl sulfate is designed to produce porous agglomerates with a dissolution wetting rate compatible with reconstituted oral suspension or direct top-dressing onto feed. The granulation charge includes microcrystalline cellulose or lactose monohydrate, a binder such as pregelatinised starch at 2–5 wt%, and magnesium lauryl sulfate at 0.1–0.8 wt% of dry charge mass. The top-spray process is operated at an inlet air temperature of 50–60 °C, an atomisation air pressure of 1.0–1.5 bar, and a spray rate of 10–15 g/min per kilogram of dry charge; product temperature is held between 30 and 38 °C to prevent excessive evaporation that would densify the granule shell and trap poorly wetted active particles inside. Because the surfactant lowers binder surface tension, droplet size decreases and the spray tends to generate broader granule size distribution; therefore the nozzle position is set 200–300 mm above the product bed and the product bowl is fitted with a sieve insert to discharge only granules passing through 1.00 mm and retained on 250 µm as specified in USP <786>. Granule flow is assessed by USP <616> with a Carr index below 15%, and moisture is limited to 1.0–2.0% by USP <731> to avoid interparticle liquid bridges during storage. The finished granules for oral paste or drench reconstitution contain magnesium lauryl sulfate as an internal wetting agent that allows glycerol-containing aqueous vehicles to penetrate the granule matrix in less than 60 s when shaken at 200 oscillations/min; wetting time is measured by the sinking time test in 500 mL purified water at 25 °C. If wetting time exceeds 120 s, the batch is rejected because the granule structure is too dense and the active substance may not disperse uniformly in the thickened vehicle.

For feed premix applications, the compound is restricted to wetting and anti-caking functions in medicated premixes for oral group medication of pigs, poultry, and ruminants, with the compound incorporated at 0.1–0.5 wt% relative to the active component rather than to the final feed. Regulatory compliance for this sector follows EU Regulation 2019/4 for medicated feed and, in the United States, current good manufacturing practice for medicated feeds under 21 CFR Part 225. The premix is manufactured in a horizontal ribbon mixer with a working capacity of 60–80%, operated at 40–60 rpm for 8–12 min after a two-stage dilution: first a 1:10 preblend with colloidal silica and magnesium lauryl sulfate, then geometric dilution into the carrier. Homogeneity is evaluated by taking 10 thief samples from different zones and assaying active substance by HPLC; the acceptance criterion is RSD ≤ 5.0%. The magnesium lauryl sulfate content is also checked by a validated ion chromatography method to ensure surfactant distribution does not deviate by more than ±10% of labelled concentration. The terminal premix is diluted into complete feed at 1–10 kg/tonne, and the surfactant improves wetting of hydrophobic active particles in the aqueous environment of the upper digestive tract; however, it may reduce the stability of water-soluble vitamins if stored above 30 °C and 65% RH for more than 90 days, so protected vitamin forms are used in the premix.

To Stabilise Aqueous Solutions Without Foam Entrainment Under High-Shear Mixing

Aqueous veterinary solutions for otic, dermal, and oral use employ magnesium lauryl sulfate as a micellar solubiliser for poorly water-soluble actives and as a contact-angle reducer for spreadability on hydrophobic skin and ear canal surfaces. The effective concentration in finished solutions is usually 0.05–0.5 wt%, with the lower bound applied to otic drops to avoid excessive cerumen emulsification and the upper bound applied to pour-on products where spreading over the hair coat must be rapid and uniform. The solution is prepared by dissolving the surfactant in purified water at 40–45 °C with gentle propeller agitation at 200–400 rpm; high-shear mixing above 2,000 rpm is contraindicated because air entrainment produces a stable foam head that can persist for more than 30 min and interfere with volumetric filling. After cooling to 25 ± 2 °C, the active substance is added under continuous mixing until complete dissolution or micellar dispersion; clarity is checked by laser nephelometry with a target nephelometric turbidity unit value below 10 NTU for clear solutions. The formulation must be protected against light-induced oxidation of the lauryl chain; amber polyethylene terephthalate bottles with nitrogen headspace are used, and dissolved oxygen is reduced to below 0.5 mg/L by nitrogen sparging before filling. Finished solution quality is controlled by pH measurement under USP <791>, with typical otic formulations buffered between 5.0 and 7.0; osmolality by USP <785> for otic preparations is adjusted to 260–320 mOsm/kg with sodium chloride or glycerol. Preservative effectiveness is evaluated by USP <51>; magnesium lauryl sulfate can reduce the activity of cationic preservatives through ionic complexation, so the preservative system must be selected from benzyl alcohol or phenoxyethanol rather than benzalkonium chloride. The terminal solution for dermal spray is packaged with a metered spray pump delivering 0.5 mL per actuation; the viscosity of the solution is maintained below 20 mPa·s at 25 °C using a Brookfield rotational viscometer to prevent nozzle clogging.